SAB Biotherapeutics (NASDAQ:SABS) Issues Earnings Results

SAB Biotherapeutics (NASDAQ:SABS) released its earnings results on Monday. The company reported ($0.46) earnings per share (EPS) for the quarter, FiscalAI reports.

Here are the key takeaways from SAB Biotherapeutics’ conference call:

• SAB-142 is a human anti-thymocyte globulin (built on the Tc Bovine platform) and is in a pivotal Phase IIb SAFEGUARD study for newly diagnosed Type 1 diabetes, giving the company a unique platform and long-term exclusivity versus rabbit-derived ATG approaches.
• Phase I data showed 0% serum sickness and induction of durable PD-1/TIGIT exhaustion plus a Treg-sparing profile, supporting the claim that SAB-142 may match Thymoglobulin efficacy while being safer and redosable.
• SAFEGUARD is a global pivotal Phase IIb (adults/adolescents/pediatrics) with two active doses (2.5 and 1.5 mg/kg) versus placebo, a one-year C-peptide primary endpoint (80% powered for a 40% preservation effect), and management says enrollment is on track.
• Regulatory risk remains — FDA views SAFEGUARD as pivotal but has not confirmed that C-peptide alone is sufficient for approval, so the upcoming decision on Sanofi’s Tzield could materially affect SAB’s approval pathway.
• Financially, SAB reported $144M cash at end-2025 and holds $175M in enrollment warrants (strike $1.75), which management says funds the company through SAFEGUARD and could extend to launch if exercised.

SAB Biotherapeutics Stock Performance

SABS stock traded up $0.05 on Monday, reaching $3.84. 174,923 shares of the company were exchanged, compared to its average volume of 375,147. The firm has a market capitalization of $182.82 million, a PE ratio of -1.24 and a beta of 0.59. SAB Biotherapeutics has a 12 month low of $1.00 and a 12 month high of $6.60. The stock’s fifty day moving average price is $3.97 and its 200 day moving average price is $3.31. The company has a debt-to-equity ratio of 0.02, a current ratio of 10.49 and a quick ratio of 10.50.

Institutional Trading of SAB Biotherapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of SABS. State of Wyoming acquired a new position in shares of SAB Biotherapeutics during the fourth quarter valued at about $34,000. State Street Corp bought a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at about $49,000. ADAR1 Capital Management LLC bought a new position in SAB Biotherapeutics during the third quarter valued at about $30,000. Fifth Lane Capital LP bought a new position in SAB Biotherapeutics during the fourth quarter valued at about $56,000. Finally, Dimensional Fund Advisors LP bought a new position in SAB Biotherapeutics during the third quarter valued at about $32,000. 7.82% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SABS has been the topic of a number of research analyst reports. Guggenheim began coverage on shares of SAB Biotherapeutics in a research note on Friday, December 19th. They issued a “buy” rating and a $15.00 target price on the stock. Weiss Ratings restated a “sell (d)” rating on shares of SAB Biotherapeutics in a report on Monday, December 29th. UBS Group initiated coverage on SAB Biotherapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating and a $7.00 price target on the stock. Wall Street Zen upgraded SAB Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Finally, Chardan Capital reissued a “buy” rating and set a $12.00 price objective on shares of SAB Biotherapeutics in a research report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.